Tedra Gray
Acute Care · Chicago, ILNPI 1659358760
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (48.3%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. 37 manufacturers reported payments, led by Regeneron Healthcare Solutions, Inc. at 29.3% of the total. 2025 is the largest year on record at $35,043, 8.6 times the $4,098 reported in 2021. Among acute care clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 363 payments — averaging $213.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$23K
- Phathom Pharmaceuticals, Inc.$17K
- Evoke Pharma, Inc.$11K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$10K
- Ardelyx, Inc.$6K
- Sanofi$3K
- plus $7K from 31 others
What the payments were for
- Consulting fees$11,21314%
- Speaking & faculty fees$37,43648%
- Travel & lodging$16,77922%
- Food & beverage$12,06116%
- Education$790%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 62 | $22,752 |
| Phathom Pharmaceuticals, Inc. | 57 | $17,495 |
| Evoke Pharma, Inc. | 13 | $11,224 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 43 | $10,115 |
| Ardelyx, Inc. | 20 | $6,444 |
| Sanofi | 11 | $2,551 |
| Regeneron | 2 | $1,434 |
| Takeda Pharmaceuticals U.S.A., Inc. | 21 | $1,044 |
| Johnson & Johnson | 28 | $800 |
| Lilly USA, LLC | 13 | $454 |
| Mahana Therapeutics, Inc. | 1 | $405 |
| AbbVie | 16 | $402 |
| Bristol Myers Squibb | 4 | $333 |
| Madrigal Pharmaceuticals | 5 | $286 |
| Modernatx, Inc. | 1 | $250 |
| AstraZeneca | 12 | $225 |
| Gilead | 5 | $164 |
| Incyte Corporation | 9 | $157 |
| Intercept Pharmaceuticals, Inc. | 3 | $151 |
| Seagen Inc. | 7 | $128 |
| Ipsen Biopharmaceuticals, Inc | 5 | $113 |
| Merck | 4 | $98 |
| Janssen Scientific Affairs, LLC | 1 | $91 |
| Genentech USA, Inc. | 2 | $58 |
| Daiichi Sankyo Inc. | 2 | $51 |
| Servier Pharmaceuticals LLC | 2 | $48 |
| Novo Nordisk | 2 | $46 |
| Bayer | 2 | $43 |
| ADC Therapeutics America, Inc. | 2 | $40 |
| EMD Serono, Inc. | 1 | $30 |
| Pharmacosmos Therapeutics Inc. | 1 | $25 |
| Novartis | 1 | $24 |
| Puma Biotechnology, Inc. | 1 | $20 |
| Sobi, Inc | 1 | $20 |
| Livanova USA, Inc. | 1 | $18 |
| Epizyme, Inc. | 1 | $17 |
| Coherus Oncology, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$77,569 in reported general payments places this provider in the 95th percentile of 461 acute care providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LinzessLinaclotide | 17 | $16,838 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 43 | $668 |
| Famotidine | 13 | $206 |
| Omeprazole | 12 | $167 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess | $402 | $16,83817 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 461 acute care providers in Illinois.
Other acute care in Chicago
- Gwen CassidyChicago$46K
- Erin DarguzasChicago$17K
- Sarah MiyataChicago$11K
- Katie MeadorChicago$10K
- Viktoriya KaganChicago$8K
- Laura RitchieChicago$5K
- Christine Joy LocquiaoChicago$5K
- Janice AmslerChicago$5K
- Julie MudgeChicago$3K
- Tonia JacobChicago$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.